OpenAlex
PricingAboutJobs
Log inGet started
Work

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

HTML

Year: 2009
Type: review
Source: Biomarkers
DOI: 10.1080/13547500902777608
Authors: M.A. Karsdal, K. Henriksen, D.J. Leeming, P. Mitchell, K. Duffin, N. Barascuk, L. Klickstein, P. Aggarwal, O. Nemirovskiy, I. Byrjalsen, P. Qvist, A.C. Bay-Jensen, E.B. Dam, S.H. Madsen, C. Christiansen
Institutions: Nordic Bioscience (Denmark), Eli Lilly (United States), Novartis (Switzerland), Pfizer (United States)
Language: English

Topic: Biosimilars and Bioanalytical Methods
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: neoantigens, biochemical markers, tissue degradation, drug development, translational research
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2132302127
FWCI: 1.188
Cites: 161
Cited by: 140
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security